JP5347028B2 - バイオマーカーとしてのＥＥＦ１Ａの使用およびＭｅｔＡＰ２阻害剤をスクリーニングするための方法 - Google Patents

バイオマーカーとしてのＥＥＦ１Ａの使用およびＭｅｔＡＰ２阻害剤をスクリーニングするための方法 Download PDF

Info

Publication number
JP5347028B2
JP5347028B2 JP2011533565A JP2011533565A JP5347028B2 JP 5347028 B2 JP5347028 B2 JP 5347028B2 JP 2011533565 A JP2011533565 A JP 2011533565A JP 2011533565 A JP2011533565 A JP 2011533565A JP 5347028 B2 JP5347028 B2 JP 5347028B2
Authority
JP
Japan
Prior art keywords
metap2
meteef1a
compound
activity
eef1a
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2011533565A
Other languages
English (en)
Japanese (ja)
Other versions
JP2012507268A (ja
JP2012507268A5 (enExample
Inventor
ローラント ケルナー、
フランク ツェンケ、
イェルク ボンケ、
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck Patent GmbH
Original Assignee
Merck Patent GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent GmbH filed Critical Merck Patent GmbH
Publication of JP2012507268A publication Critical patent/JP2012507268A/ja
Publication of JP2012507268A5 publication Critical patent/JP2012507268A5/ja
Application granted granted Critical
Publication of JP5347028B2 publication Critical patent/JP5347028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Cell Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
JP2011533565A 2008-11-06 2009-10-05 バイオマーカーとしてのＥＥＦ１Ａの使用およびＭｅｔＡＰ２阻害剤をスクリーニングするための方法 Active JP5347028B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP08019432.7 2008-11-06
EP08019432 2008-11-06
PCT/EP2009/007102 WO2010051882A1 (en) 2008-11-06 2009-10-05 Use of eef1a as biomarker and a method of screening metap2 inhibitors

Publications (3)

Publication Number Publication Date
JP2012507268A JP2012507268A (ja) 2012-03-29
JP2012507268A5 JP2012507268A5 (enExample) 2012-11-22
JP5347028B2 true JP5347028B2 (ja) 2013-11-20

Family

ID=41409225

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2011533565A Active JP5347028B2 (ja) 2008-11-06 2009-10-05 バイオマーカーとしてのＥＥＦ１Ａの使用およびＭｅｔＡＰ２阻害剤をスクリーニングするための方法

Country Status (8)

Country Link
US (1) US9151743B2 (enExample)
EP (1) EP2344665B1 (enExample)
JP (1) JP5347028B2 (enExample)
AU (1) AU2009313167C1 (enExample)
CA (1) CA2742737C (enExample)
ES (1) ES2402564T3 (enExample)
IL (1) IL212664A0 (enExample)
WO (1) WO2010051882A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015069489A1 (en) 2013-11-06 2015-05-14 Merck Patent Gmbh Predictive biomarker for hypoxia-activated prodrug therapy
KR101712982B1 (ko) * 2015-07-31 2017-03-07 고려대학교 산학협력단 비알콜성지방간 조절인자 14-3-3 단백질
WO2018148638A1 (en) * 2017-02-10 2018-08-16 Zafgen, Inc. Pharmaceutical compositions of metap-2 inhibitors
CN108611352B (zh) * 2018-04-20 2020-08-07 华南农业大学 一种拟禾本科根结线虫翻译延长因子Mg-eEF1A及其防治植物病害的应用
CA3170118A1 (en) * 2020-02-06 2021-08-12 The Regents Of The University Of California Elongation factor 1-alpha inhibitors and uses thereof
CN116395718B (zh) * 2023-04-12 2024-12-17 中国科学院长春应用化学研究所 一种弱碱性钠盐纳米药物、其制备方法及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998056372A1 (en) * 1997-06-09 1998-12-17 Massachusetts Institute Of Technology TYPE 2 METHIONINE AMINOPEPTIDASE (MetAP2) INHIBITORS AND USES THEROF
EP1337854A2 (en) * 2000-11-14 2003-08-27 Novartis AG Method for screening anti-proliferative compounds and inhibiting tumor growth
US20020182701A1 (en) * 2001-08-30 2002-12-05 Saint Louis University Dominant negative variants of methionine aminopeptidase 2 (MetAP2) and clinical uses thereof
US20030232383A1 (en) 2001-11-02 2003-12-18 Sylvia Daunert Novel reagentless sensing system for measuring carbohydrates based on the galactose/glucose binding protein

Also Published As

Publication number Publication date
US20110275088A1 (en) 2011-11-10
EP2344665B1 (en) 2013-01-23
AU2009313167C1 (en) 2014-06-12
IL212664A0 (en) 2011-07-31
AU2009313167A1 (en) 2011-06-23
US9151743B2 (en) 2015-10-06
ES2402564T3 (es) 2013-05-06
CA2742737C (en) 2018-05-29
CA2742737A1 (en) 2010-05-14
JP2012507268A (ja) 2012-03-29
WO2010051882A1 (en) 2010-05-14
EP2344665A1 (en) 2011-07-20

Similar Documents

Publication Publication Date Title
US8119355B2 (en) Biomarkers for cancer sensitivity and uses thereof
JP5347028B2 (ja) バイオマーカーとしてのＥＥＦ１Ａの使用およびＭｅｔＡＰ２阻害剤をスクリーニングするための方法
CN104364649B (zh) 用于鉴定具有基因毒性的化合物的蛋白表达分析
AU2009313167B2 (en) Use of EEF1A as biomarker for screening of MetAP2 inhibitors
US11726091B2 (en) Compositions and methods of diagnosing pancreatic cancer
CN102472753A (zh) 基于组蛋白macroH2A同工型预测癌症复发风险的诊断方法
EP2546269B1 (en) Monoclonal antibody against necrosis marker prdx4 and use thereof
CN109633165B (zh) 抗hspa4自身抗体作为乳腺癌诊断或预后评估标志物的应用
US9663567B2 (en) Monoclonal antibodies against serotransferrin antigens, and uses therefor
TW201226903A (en) Methods and compositions for detection of lethal system and uses thereof
JP5721628B2 (ja) 癌診断用マーカーとしてのプロテインキナーゼＣα
WO2011009523A1 (en) Eg5 as biomarker in rare thoracic cancer
JP4795353B2 (ja) 腫瘍疾患および慢性炎症性腸疾患の診断のための液性バイオマーカーとしてのカルバモイルリン酸合成酵素１（ｃｐｓ１）の使用
US9977026B2 (en) Detection of elevated levels of phosphorylated MCM and method of increasing MCM phosphorylation capacity
CN115166242A (zh) 用于诊断纤维化疾病的试剂盒、方法和计算机可读介质
JP3524536B2 (ja) 癌の診断、モニタリング、ステージング、イメージングおよび処置のための新規方法
KR102325742B1 (ko) 암의 진단용 조성물
US20220323498A1 (en) Assay for immune cell recovery
CN119548517A (zh) 一种m2巨噬细胞的诱导剂及应用
AU2012326434A1 (en) Predictive biomarkers for breast cancer

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20121004

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20121004

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20121106

A975 Report on accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A971005

Effective date: 20121121

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20121218

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130416

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20130716

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20130806

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20130819

R150 Certificate of patent or registration of utility model

Ref document number: 5347028

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250